# Genetic Expression in Schizophrenics Treated With SSRI Augmentation: Relationship to Clinical and Cognitive Function

> **NCT00645580** · NA · UNKNOWN · sponsor: **Sha'ar Menashe Mental Health Center** · enrollment: 15 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Fluvoxamine

## Key facts

- **NCT ID:** NCT00645580
- **Lead sponsor:** Sha'ar Menashe Mental Health Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-04
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2009-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00645580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00645580, "Genetic Expression in Schizophrenics Treated With SSRI Augmentation: Relationship to Clinical and Cognitive Function". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00645580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*